In general, the descriptive statistics on metabolic (fasting plasma glucose, insulin, cholesterol and triglyceride) and inflammatory markers (interferon γ and interleukins 1β, 6 and 8) and other markers and scores reflecting fibrosis status (aspartate aminotransferase to platelet ratio index [APRI], Fibrosis-4 score [Fib-4 score], enhanced liver fibrosis [ELF] score, NAFLD fibrosis score and Pro-C3) did not show relevant trends over time or differences for any BI 1467335 dose (Supplementary Tables 13–25). This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.